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a deleterious BRCA1 mutation and UWB1.289-BRCA1 restored which had a functional BRCA1 gene inserted. All cells were cultured in RPMI 1640 with 10% FBS and 1% penicillin/streptomycin, except for UWB1.289 which was cultured in a 1:1 solution of MEGM with bullet kit: RPMI 1640 with 10% FBS and 1$ penicillin/stretomycin. PARP1 Radioligand Binding in Live OVCAR8 Cells. The affinity of each compound for the PARP1 enzyme was evaluated using a radioligand binding method previously reported by our group. 6 Briefly, OVCAR8 ovarian cancer cells were seeded in 96-well Stripwell plates at a density of 40,000 cells/well 24 hrs prior to the study. On the day of study, compounds were diluted in RPMI to concentrations of 100 µM -0.064 nM. Next, [ 125 I]KX1, a known PARP1 specific radioligand, was added to the plate followed by each compound dilution. Reactions were allowed to equilibrate for 1 hr and were then washed with 200 µL of PBS. Wells were separated and counted on an automatic Wizard gamma counter (Perkin Elmer, Waltham MA). Dose response curves were produced to calculate 50% maximum inhibition values (IC50) using non-linear fit sigmoidal dose response curves in GraphPad 7.0 (Prism, La Jolla CA). Experiments were repeated three times with adjusting dose concentrations to increase accuracy of IC50 values.
Cell Viability Assays. Cell viability assays were carried out using UWB1.289 and UWB1.289-BRCA1 following previously reported methods. 6 Briefly, cells were seeded in black wall clear bottom 96-well plates at concentrations of 1,000 cells/well. After 24 h, cells were then treated with concentrations from 100-0.016 µM. Cells were incubated with compounds for 4-7 days and then assayed for cell viability using the luminescent based assay, CellTiter Glo (Promega, Waltham MA). Plates were read on an Enspire multimode plate reader (Perkin Elmer). Data was normalized to percent survival at each concentration evaluated by diving the luminescent signal in treated wells vs. the average of vehicle controls. Experiments were repeated three times and all compounds were assayed during each experiment.
Pgp-Glo™ Assay. P-gp activity of each compound was measured using Promega Pgp-Glo™ Assay Systems. 25µg of diluted recombinant human P-gp membranes were added to untreated white opaque multiwell plates along with Pgp-Glo™ Assay Buffer, a non-limiting concentration of ATP (5mM) and 20µl of each test compound (20µM) for 1 hr at 37°C. Untreated and Na3VO4-treated control samples were also tested in addition to Verapamil-treated samples (positive control). After incubation, 50µl of ATP Detection Reagent was added to all wells to stop the P-gp reaction. Samples were mixed briefly on a plate shaker then incubated plate at room temperature for 20 minutes to allow luminescent signal to develop. Luminescence was read on a plate-reading luminometer. This luciferase-based detection reaction provides a linear response to ATP concentration in each sample. Thus any changes in signal directly reflect changes in ATP concentration. 
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Characterization of Compounds 2-3, and 5-10
(2) -4-(4-Fluoro-3-(3-methoxyazetidine-1-carbonyl)benzyl)phthalazin-1(2H)-
